Rhythm Pharmaceuticals Statistics
Total Valuation
RYTM has a market cap or net worth of $3.54 billion. The enterprise value is $3.35 billion.
Important Dates
The next estimated earnings date is Thursday, February 20, 2025, before market open.
Earnings Date | Feb 20, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
RYTM has 61.46 million shares outstanding. The number of shares has increased by 6.06% in one year.
Current Share Class | 61.46M |
Shares Outstanding | 61.46M |
Shares Change (YoY) | +6.06% |
Shares Change (QoQ) | +0.34% |
Owned by Insiders (%) | 0.57% |
Owned by Institutions (%) | 84.29% |
Float | 45.06M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 30.87 |
Forward PS | 21.59 |
PB Ratio | n/a |
P/TBV Ratio | 732.34 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 29.77 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.49, with a Debt / Equity ratio of 0.74.
Current Ratio | 3.49 |
Quick Ratio | 3.25 |
Debt / Equity | 0.74 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -13.47 |
Financial Efficiency
Return on equity (ROE) is -147.90% and return on invested capital (ROIC) is -71.39%.
Return on Equity (ROE) | -147.90% |
Return on Assets (ROA) | -46.24% |
Return on Capital (ROIC) | -71.39% |
Revenue Per Employee | $497,920 |
Profits Per Employee | -$1.16M |
Employee Count | 226 |
Asset Turnover | 0.31 |
Inventory Turnover | 1.18 |
Taxes
In the past 12 months, RYTM has paid $632,000 in taxes.
Income Tax | 632,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +40.16% in the last 52 weeks. The beta is 2.17, so RYTM's price volatility has been higher than the market average.
Beta (5Y) | 2.17 |
52-Week Price Change | +40.16% |
50-Day Moving Average | 58.39 |
200-Day Moving Average | 48.37 |
Relative Strength Index (RSI) | 53.14 |
Average Volume (20 Days) | 602,965 |
Short Selling Information
The latest short interest is 5.27 million, so 8.57% of the outstanding shares have been sold short.
Short Interest | 5.27M |
Short Previous Month | 5.81M |
Short % of Shares Out | 8.57% |
Short % of Float | 11.68% |
Short Ratio (days to cover) | 9.84 |
Income Statement
In the last 12 months, RYTM had revenue of $112.53 million and -$261.57 million in losses. Loss per share was -$4.33.
Revenue | 112.53M |
Gross Profit | 99.72M |
Operating Income | -265.51M |
Pretax Income | -258.09M |
Net Income | -261.57M |
EBITDA | -263.92M |
EBIT | -265.51M |
Loss Per Share | -$4.33 |
Full Income Statement Balance Sheet
The company has $298.39 million in cash and $113.27 million in debt, giving a net cash position of $185.12 million or $3.01 per share.
Cash & Cash Equivalents | 298.39M |
Total Debt | 113.27M |
Net Cash | 185.12M |
Net Cash Per Share | $3.01 |
Equity (Book Value) | 152.70M |
Book Value Per Share | 0.18 |
Working Capital | 242.74M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$124.42 million and capital expenditures $1,000, giving a free cash flow of -$124.42 million.
Operating Cash Flow | -124.42M |
Capital Expenditures | 1,000 |
Free Cash Flow | -124.42M |
FCF Per Share | -$2.02 |
Full Cash Flow Statement Margins
Gross margin is 88.61%, with operating and profit margins of -235.95% and -230.11%.
Gross Margin | 88.61% |
Operating Margin | -235.95% |
Pretax Margin | -229.55% |
Profit Margin | -230.11% |
EBITDA Margin | -234.53% |
EBIT Margin | -235.95% |
FCF Margin | n/a |
Dividends & Yields
RYTM does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -6.06% |
Shareholder Yield | -6.06% |
Earnings Yield | -7.40% |
FCF Yield | -3.52% |
Dividend Details Analyst Forecast
The average price target for RYTM is $66.90, which is 16.31% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $66.90 |
Price Target Difference | 16.31% |
Analyst Consensus | Strong Buy |
Analyst Count | 10 |
Revenue Growth Forecast (5Y) | 62.20% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
RYTM has an Altman Z-Score of 1.41 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.41 |
Piotroski F-Score | 3 |